Longer follow up of a real-world study of cemiplimab in advanced cutaneous squamous cell carcinoma: Focus on late toxicities and long term benefit

This content was selected by and is provided by Sanofi.

© Copyright 2023 European Society for Medical Oncology (ESMO). All rights reserved.

This selection of Meeting presentations was made by Sanofi and ESMO did not participate in the selection. This selection of presentations does not necessarily represent a balanced view or full discussion of any given subject. Any summaries or commentary appearing herein were not prepared or reviewed by ESMO. The ideas and opinions expressed herein do not necessarily reflect the views of ESMO or Springer Healthcare.

The mention of any company, product, service, or therapy in this collection of materials does not constitute an endorsement of any kind by ESMO. It is the responsibility of the treating physician or other health care provider, relying on independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient. Viewers are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify, among other matters, the dosage, method, and duration of administration, or contraindications. Viewers are also encouraged to contact the manufacturer with questions about the features or limitations of any products. ESMO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the material contained in this publication or to any errors or omissions.